<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01550770</url>
  </required_header>
  <id_info>
    <org_study_id>CI-10-0005</org_study_id>
    <nct_id>NCT01550770</nct_id>
  </id_info>
  <brief_title>Exploratory Study of Propofol and Fentanyl Pharmacodynamics</brief_title>
  <official_title>An Open Label, Exploratory Study of Propofol and Fentanyl Pharmacodynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ethicon Endo-Surgery</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ethicon Endo-Surgery</source>
  <brief_summary>
    <textblock>
      Exploration of the hypothesis that general anesthesia is not a singular threshold but is a&#xD;
      continuum of central nervous system depression dependent on interpretation of nociceptive&#xD;
      stimuli.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between Modified Observers Assessment of Alertness (MOAAS) and transdermal electrical stimulation (TES)</measure>
    <time_frame>1 day</time_frame>
    <description>MOAAS and TES assessment of increasing level(s) of sedation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>General Anesthesia</condition>
  <arm_group>
    <arm_group_label>proprofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>peripheral IV of propofol at increasing dose levels</description>
    <arm_group_label>proprofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesia (ASA) classification score I-II male and female&#xD;
             volunteers&#xD;
&#xD;
          -  Normal healthy individual by medical history and physical examination&#xD;
&#xD;
          -  Uncomplicated airway anatomy&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18-29&#xD;
&#xD;
          -  Subject willing to give consent and comply with evaluation and treatment schedule&#xD;
&#xD;
          -  18-55 years of age (inclusive)&#xD;
&#xD;
          -  Negative durg screen for marijuana, cocaine, ecstasy, phencyclidine (PCP),&#xD;
             amphetamines, benzodiazepines, opiates and methamphetamines&#xD;
&#xD;
          -  Woman of childbearing age byst be utilizing reliable means of contraception&#xD;
&#xD;
          -  Able to read, speak and understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Physical of psychological condition which would impair study participation as&#xD;
             determined by the principal investigator&#xD;
&#xD;
          -  Known or suspected neurological pathologies as assessed by the principal investigator&#xD;
&#xD;
          -  History of significant alcohol or drug abuse, a history of allergy to opioids or&#xD;
             propofol, or a history of chronic drug requirement or medical illness that is known to&#xD;
             alter pharmacokinetics or pharmacodynamics of fentanyl and/or propofol&#xD;
&#xD;
          -  Known or suspected hypersensitivity to any study drug&#xD;
&#xD;
          -  Taken any medication within 2 days prior to study drug administration, with the&#xD;
             exception of oral contraceptives&#xD;
&#xD;
          -  Baseline tolerance above 50 mA on TES&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Consumed food within 8 hours or liquids within 4 hours prior to study drug&#xD;
             administration&#xD;
&#xD;
          -  Participation in any other investigational device or durg study within 30 days of&#xD;
             enrollment&#xD;
&#xD;
          -  Diagnosis of sleep apnea&#xD;
&#xD;
          -  Current prescription to anti-depressant or anti-anxiety medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Talmage Egan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>March 5, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <last_update_submitted>July 20, 2012</last_update_submitted>
  <last_update_submitted_qc>July 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

